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ABSTRACT
Aims To examine possible beneﬁts of intravitreal
bevacizumab (IVB) pretreatment in vitrectomy for severe
diabetic retinopathy.
Methods A comprehensive literature search was
performed using the Cochrane Collaboration
methodology to identify randomised controlled trials and
comparative studies of vitrectomy with or without IVB
pretreatment for severe or complicated diabetic
retinopathy. Meta-analyses were performed for
intraoperative (including intraoperative bleeding,
endodiathermy, iatrogenic retinal tears and mean
surgical time) and postoperative outcome parameters
(including best-corrected visual acuity, recurrent vitreous
haemorrhage, reabsorption time of blood and other
complications).
Results Six randomised controlled trials and one
comparative study were identiﬁed and used for
comparing vitrectomy alone (142 eyes, control group)
with vitrectomy with IVB pretreatment (139 eyes). The
intraoperative ﬁndings showed that the incidence of
intraoperative bleeding and frequency of endodiathermy
were statistically signiﬁcantly less in the IVB
pretreatment group (p<0.01) than in the vitrectomy
alone group. The IVB pretreatment group took
signiﬁcantly less surgical time than the control group
(p¼0.003). Postoperative results indicated that
reabsorption time of blood was signiﬁcantly shorter
(p¼0.04), incidence of recurrent VH was almost
signiﬁcantly less (p¼0.05), and ﬁnal best-corrected
visual acuity was signiﬁcantly better (p¼0.003) in the
IVB group than in the control group. Other complications,
including ﬁnal retinal detachment, and reoperation, were
statistically insigniﬁcant.
Conclusion IVB pretreatment in vitrectomy can achieve
excellent clinical outcomes for severe diabetic
retinopathy. It potentially facilitates surgeons’
manoeuvres and reduces intra- and postoperative
complications.
INTRODUCTION
Recently, numerous studies have reported clinical
outcomes of intravitreal bevacizumab (IVB) as an
adjunct to vitrectomy in the management of
diabetic retinopathy.
1e10 Bevacizumab can induce
regression of retinal neovascularisation in patients
with diabetes; therefore, it was suggested that a
presurgical administration of IVB may reduce
intraoperative bleeding during vitrectomy in
proliferative diabetic retinopathy (PDR).
13 e6
However, the presurgical administration of IVB
remains controversial. Some studies reported that
bevacizumab pretreatment for diabetic vitrectomy
did not inﬂuence rates of postoperative vitreous
haemorrhage or ﬁnal visual acuity.
71 0
Although many surgeons perform IVB before
vitrectomy in patients with diabetes, systematic or
larger sample size studies demonstrating its beneﬁts
in facilitation of surgery and clinical outcomes are
limited. Therefore, it is necessary to review in
greater depth the available studies to understand
the beneﬁts of IVB pretreatment. In an attempt to
detect beneﬁts in safety and efﬁcacy as the primary
comparative criteria, we performed a system review
and meta-analysis of existing RCTs and high-
quality comparative studies of vitrectomy with or
without IVB pretreatment for the treatment of
severe or complicated diabetic retinopathy.
MATERIALS AND METHODS
This meta-analysis was performed according to
a predetermined protocol described previously.
11 12
Literature search
Tworeviewersindependentlysearchedthefollowing
electronic databases: PubMed, EMBASE and the
Cochrance Controlled Trials Register up to 30 April
2010. For maximum sensitivity, we used free text
andthesaurustermsincluding‘vitrectomy,’‘diabetic
retinopathy’ and ‘bevacizumab.’ Full articles were
retrieved, when titles and/or abstracts met this
objective. A manual cross-reference search of the
bibliographiesofrelevantarticleswasconducted.All
published studies comparing vitrectomy alone
versus vitrectomy with IVB pretreatment for dia-
betic retinopathy were included, if they met the
inclusion criteria. The search included RCTs and
high-qualitycomparativestudies.Foraninclusionin
themeta-analysis,thepatientsintheselectedstudies
had to present with severe diabetic retinopathy and
be older than 18 years of age. At least one or more
clinicaloutcomes representingintraoperative and/or
postoperative outcome parameters must be assessed
and published. There was no language restriction on
the publications.
Discordance about study inclusion between the
two reviewers was resolved through discussion
until 100% agreement was reached on the ﬁnal
interpretation of the data.
Quality assessment of retrieved articles
The selected studies were appraised by two
reviewers, who independently assessed their quality
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Clinical scienceusing the methods recommended in the Cochrane Handbook for
Systematic Reviews of Interventions.
13 Methodological quality
included allocation concealment, method of allocation to treat-
ment, masking of outcome assessment and completeness of
follow-up.
Outcome measure
The intraoperative outcome parameters included incidence of
intraoperative bleeding, frequency of endodiathermy, iatrogenic
retinal tears and mean surgical time. Postoperative outcome
parameters included best-corrected visual acuity (BCVA), recur-
rent vitreous haemorrhage (VH), reabsorption time of blood,
early and late elevation of intraocular pressure (IOP), ﬁnal retinal
detachment (RD) and repeat vitrectomy.
Data extraction and analysis
The studies were tabulated and methodologically evaluated to
assess homogeneity. Any heterogeneity between the studies
would not be justiﬁed to pool the assessed outcomes. A
customised data-extraction form, as described in the Cochrane
Handbook for Systematic Reviews of Interventions, was used to
record the duration of the trial, sample size, dropouts, the
system and ocular baseline features, the type of surgery and
differential treatment, the dosage and time of bevacizumab
injection.
Statistical analysis
Quantitative data were analysed using the Cochrane Review
Manager (RevMan) version 4.2 software. Summary estimates,
including 95% CIs, were calculated. For continuous outcome
data (eg, mean surgical time), means and standard deviations
were used to calculate a weighted mean difference (WMD). For
dichotomous outcomes (eg, proportions of intraoperative
bleeding), the OR was calculated.
Statistical heterogeneity was tested using the Q statistic of
the c
2 value test and I
2 test. Fixed-effects models were used,
unless signiﬁcant evidence of statistical heterogeneity or clinical
diversity was found. For results showing signiﬁcant heteroge-
neity (I
2>50%), a random-effects meta-analysis was performed
by the DerSimonianeLaird method. Outcome measures were
assessed on an intent-to-treat basis. A p value of <0.05 was
considered statistically signiﬁcant. A sensitivity analysis was
performed by excluding the non-randomised study.
Publication bias was assessed by visually inspecting a funnel
plot.
RESULTS
Six RCTs and one comparative study published between 2008
and 2010 met the inclusion criteria.
1e6 9 In di Lauro’s study, the
group of IVB 7 days prior to vitrectomy was selected to the IVB
group.
9 The present meta-analysis involved 142 eyes treated
with vitrectomy alone and 139 eyes receiving vitrectomy with
IVB pretreatment. The selection of seven studies is summarised
in tables 1, 2. Each study revealed that there were no signiﬁcant
differences in preoperative demographic features and other
factors that may have inﬂuenced surgery, such as previous
panretinal photocoagulation.
Intraoperative outcome parameters
Five studies reported data for intraoperative bleeding.
1 3569The
studies applied differential scales for the evaluation of intra-
operative bleeding. Clinically signiﬁcant intraoperative bleeding
(moderate to severe) was included in this meta-analysis.
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Clinical scienceAnalysis of these data showed that the incidence of intra-
operative bleeding was statistically signiﬁcantly less in the IVB
pretreatment group than in the vitrectomy alone group (OR
8.85; 95% CI 2.08 to 37.61; p¼0.003) (ﬁgure 1A). A sensitivity
analysis was performed to examine the effect of excluding the
non-randomised study,
6 whereby the statistical results did not
change (OR 14.51; 95% CI 3.06 to 68.85; p¼0.0008). Owing to
the poor deﬁnition and heterogeneity (I
2¼73.9%) of criteria for
the intraoperative bleeding, the result should be interpreted with
caution.
Four studies reported data for the frequency of
endodiathermy.
3e5 9 Analysis of these data showed that the
frequency of endodiathermy was statistically signiﬁcantly less in
the treatment group than in the control group (OR 15.06; 95%
CI 4.01 to 56.53; p<0.0001) (ﬁgure 1B).
Three studies reported data for the number of iatrogenic
retinal tears.
3 59Analysis of these data showed that the inci-
dence of iatrogenic retinal tears was almost signiﬁcantly less in
the IVB treatment group (OR 3.72; 95% CI 1.00 to 13.79;
p¼0.05) (ﬁgure 1C).
Five studies reported data for the mean surgical time.
1 3469
Analysis of these data showed that the mean surgical time was
statistically signiﬁcantly shorter in the treatment group than in
the control group (WMD 14.13; 95% CI 1.17 to 27.09; p¼0.03)
(ﬁgure 1D). A sensitivity analysis was performed to examine the
effect of excluding the non-randomised study,
6 and the statistical
results did not change (WMD 21.59; 95% CI 15.89 to 27.30;
p<0.00001). This comparison generated a signiﬁcant heteroge-
neity (I
2¼75.9%), and the result must be interpreted with caution.
Postoperative outcome parameters
Two studies reported data for the reabsorption time of blood
after surgery.
1 6 Analysis of these data showed that the mean
reabsorption time was statistically signiﬁcantly less in the IVB
pretreatment group than in the vitrectomy alone group (WMD
15.82; 95% CI 0.43 to 31.20; p¼0.04) (ﬁgure 2A). A sensitivity
analysis was performed to examine the effect of excluding the
non-randomised study,
6 and the statistical results did not
change (WMD 23.70; 95% CI 18.01 to 29.39; p<0.00001).
Five studies reported data for the proportion of recurrent
VH.
1 4e69The studies used differential scales for recurrent VH
evaluation. Clinical signiﬁcant recurrent VH (severe recurrent
VH with no fundus details) were included in this meta-analysis.
Furthermore, all incidences of recurrent VH during follow-ups
were included. Analysis of these data showed that the propor-
tion of recurrent VH was almost statistically signiﬁcantly less in
the treatment group than in the control group (OR 5.48; 95% CI
0.97 to 31.02; p¼0.05) (ﬁgure 2B). A sensitivity analysis was
performed to examine the effect of excluding the non-rando-
mised study,
6 whereby the statistical results did not change (OR
7.52; 95% CI 0.97 to 58.40; p¼0.05).
Owing to the poor deﬁnition and heterogeneity (I
2¼93.6%,
73.2%, respectively) of criteria for the reabsorption time and
recurrent VH, the above two results should be interpreted with
caution.
Six studies reported data for BCVA.
1 3e69Analysis of these
data showed that the mean BCVA was statistically signiﬁcantly
better in the treatment group than in the control group (WMD:
0.31; 95% CI 0.10 to 0.52; p¼0.003) (ﬁgure 2C).
Sixstudiesreporteddataforpostoperativecomplications.
1 3e69
Analysis of these data showed no statistically signiﬁcant differ-
ences in the early (<1 week) elevation of IOP ($25 mm Hg), late
($1 week) elevation of IOP ($25 mm Hg), incidence of ﬁnal RD
and proportion of repeat vitrectomy (table 3).
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Clinical sciencePublication bias
Based on a visual analysis of the funnel plots, no obvious
evidence of publication bias was found (ﬁgure 3).
DISCUSSION
The present meta-analysis revealed that IVB injection before
vitrectomy for PDR can reduce intraoperative bleeding and the
frequency of endodiathermy, and shorten the mean surgical
time. It can also shorten reabsorption time of blood after
vitrectomy, decrease the incidence of recurrent VH and improve
BCVA.
Bevacizumab is a recombinant humanised monoclonal anti-
vascular endothelial growth factor antibody used to induce
regression of neovascularisation and reduce permeability.
14 It has
increasingly been used to treat choroidal neovascularisation and
Figure 1 Forest plots of OR of proportions of intraoperative bleeding (A), frequency of endodiathermy (B), iatrogenic retinal tears (C) during
vitrectomy and forest plot of WMD of mean surgical time (D) comparing vitrectomy alone to vitrectomy with intravitreal bevacizumab (IVB)
pretreatment. PPV, pars plana vitrectomy; WMD, weighted mean difference.
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15e18 It has also proven to be effective
for the treatment of PDR complicated by VH.
19e21 Results of
ﬂuorescein angiography revealed a reduction in leakage from the
foci of neovascularisation and regression of the neovascular
component of ﬁbrovascular tissue in eyes with PDR within
1 week after IVB.
Based on these observations, it was suggested that IVB may
reduce the incidence of intraoperative and postoperative
haemorrhage in diabetic vitrectomy.
22 Chen ﬁrst reported that
preoperative IVB was helpful in facilitating vitrectomy in severe
PDR.
23 Many clinical trials proved that IVB pretreatment
ameliorates fundus conditions before vitrectomy. In Ahmadieh’s
study, owing to a signiﬁcant resolution of VH and improvement
of vision after IVB injection, nine eyes (25.7%) initially sched-
uled for vitrectomy obviated the need for surgical intervention.
5
Laboratory experiment provided objective, quantiﬁable data that
a lower number of erythrocytes retrieved from the vitrectomy
cassette were observed in those patients treated with IVB
2 weeks before surgery.
2
From surgeons’ experiences, the regression of the vascular
component of the ﬁbrovascular complexes after IVB facilitates
segmentation and delamination of membranes.
1 This is because
they are less adhesive to the underlying retina and readily
separated from the retina. The haemodynamic changes in retinal
Figure 2 Forest plots of weighted mean difference (WMD) of reabsorption time of blood (A), OR of proportions of recurrent vitreous haemorrhage (B)
and WMD of ﬁnal mean BCVA (C) after surgery comparing vitrectomy alone to vitrectomy with intravitreal bevacizumab (IVB) pretreatment. PPV, pars
plana vitrectomy.
Table 3 Postoperative complications of vitrectomy alone versus vitrectomy with intravitreal bevacizumab pretreatment in the meta-analysis
Complications No of studies
Crude rate, n/N (%)
Percentage rate
difference (95% CI)
p Value for
overall effect
Pars plana
vitrectomy group
Intravitreal bevacizumab+pars
plana vitrectomy group
Early elevation of intraocular pressure
($25 mm Hg) (#1 week)
3
135 13/66 12/67 1.08 (0.36 to 3.27) 0.89
Late elevation of intraocular pressure
($25 mm Hg) (>1 week)
3
136 8/57 0/48 17.00 (0.91 to 319.22) 0.06
Final retinal detachment 3
134 5/51 2/54 2.44 (0.52 to 11.46) 0.26
Repeat vitrectomy 2
49 3/42 1/46 2.69 (0.37 to 19.33) 0.32
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vessels, greatly reduce the likelihood of intraoperative bleeding.
Besides, decreased bleeding makes frequent adjustments of the
infusion bottle height unnecessary. Fluctuations in intraocular
pressure, which can damage the vulnerable disc, are thus
avoided. The resolution of VH and less intraoperative bleeding
may in turn provide a clear surgical ﬁeld facilitating surgery.
Some studies reported other indexes on surgical manoeuvres,
such as the frequency of required endodiathermy, and blunt and
sharp membrane dissection. The surgical complexity of the
removal of ﬁbrovascular membranes directly correlates with the
pathophysiology of PDR, type of vitreoretinal adhesion, and
degree of the intraoperative bleeding. Rizzo’s experiences
provided a more direct impression.
3 For bevacizumab-pretreated
cases, simple blunt dissection or direct membrane peeling can be
more frequent. The regression and subsequent ﬁbrosis of retinal
NV after IVB made the surgery quicker, requiring fewer tool
exchanges, thus shortening surgical time.
Two studies reported that iatrogenic retinal breaks occurred
more in the vitrectomy alone group.
3 9 It was presumed that
after IVB, vascular leakage, as well as the retinal thickness and
congestion, were reduced, and the tissue was more resistant to
traction. Less intraoperative bleeding may also provide a clear
retinal visualisation, which in turn causes fewer iatrogenic
breaks. Although the present meta-analysis does not fully
substantiate this presumption, future larger sample size
comparative clinical trials may prove it.
The rate of recurrent VH is an important factor evaluating
whether the IVB pretreatment could achieve better clinical
outcomes. The meta-analysis for all incidences of recurrent VH
during follow-ups revealed that the IVB pretreatment reduced
the rate of recurrent VH. The meta-analysis, including the early
incidences of recurrent VH (#1 week), did not change the
results (omission of statistical process). This is possible, owing
to minimal surgical trauma. The consequential effect of IVB
ought to be considered also. Previous research revealed that
bevacizumab can be detected in the retinal tissue 14 days after
intravitreal injection.
24 25 Although a great extent of the beva-
cizumab in the vitreous body stemming from the pretreatment
is possibly removed during vitrectomy, the remainder in the
retina may still have an impact. This local factor is partly
attributed to the shortened, postsurgical vitreous clear-up time.
Other factors related to the clear-up speed of the vitreous after
vitrectomy for PDR include the amount of residual blood at the
end of the operation, bleeding from surgically injured retinal
blood vessels, bleeding from unreleased ﬁbrovascular tissues,
ﬁbrin and inﬂammatory cells within the vitreous. Evidently, IVB
pretreatment could reduce these factors.
Facilitating early visual rehabilitation for patients is another
important clinical outcome. This positive effect may be due to
minimal injury to the retinal tissue during surgery, a minimal
extent of haemorrhage and posterior focal reproliferation, or
clear visual pathway after surgery in bevacizumab-treated
cases.
1 The studies included did not report apparent macular
oedema in patients with diabetes before and after vitrectomy,
but surgical manoeuvre or surgical trauma, such as delamina-
tion, could inﬂuence macular physiology function. The effect of
reducing diabetic macular oedema might play a role. Many
clinical trials have shown that IVB can reduce diabetic macular
oedema and result in a better visual recovery.
26 27
Di Lauro compared a 7-day with 20-day previtrectomy
administration of bevacizumab.
9 Clinical outcomes showed no
statistically signiﬁcant differences between the two groups, but
intraoperative severe bleeding, frequency of endodiathermy,
iatrogenic retinal break, silicone-oil tamponade, surgical mean
time and the rate of recurrent VH featured more in the 20-day
group. Concerns about potential harm of increasing vitreoretinal
traction owing to rapid neovascular involution with ﬁbrosis
contraction by IVB pretreatment must be raised. Many studies
have noted complications of aggravation of ﬁbrosis after IVB
injection for active progressive PDR.
20 23 One recent study found
that tractional retinal detachments were worsened or newly
created in 11 eyes (5.2%) of 211 IVB injections in severe PDR.
28
The time interval between IVB injection and diagnosis of trac-
tional retinal detachment was on average 13 days.
28 Ishikawa
performed IVB injections in eight eyes and found that two eyes,
injected 7 days before the operation, had severe ﬁbrosis, resulting
in some surgical complications.
22 The evidence available indi-
cates that the effect of IVB on regression of new vessels is rapid,
often evident after 24 h.
29 It seems that 3e5 days or even less
time is adequate for IVB to exert its antiangiogenic effect. A
dosage of 1.25 mg is commonly used. Some studies have revealed
that IVB at doses of 1.25 to 2.5 mg provide similar clinical
outcomes in diabetic retinopathy.
30 31 Clariﬁcation of optimal
interval time and dosage of IVB still needs an RCTwith a larger
sample size.
The selected trials revealed that no local and systemic
complications related to IVB were observed in the treatment
groups. The postoperative ﬁnal RD and repeat surgery showed
no signiﬁcant differences. These are possibly attributable to
the natural process of PDR. Long-term follow-up studies
(>6 months) are needed.
This meta-analysis may have some limitations. First, we
cannot fully exclude publication bias. The number of included
studies is insufﬁcient to carry out a further statistical test, to
detect publication bias through asymmetry plot. In addition,
we did not attempt to gain access to unpublished results.
Second, the studies included were heterogeneous in terms of
study location, population, number of patients from different
studies and basal condition. Access to individual-level data
could certainly have improved the quality of adjustment as well
as the precision of estimates. Third, there was a large disparity
in study quality (relative methodological strengths and weak-
nesses), as reﬂected by the Jadad score. This review unfortu-
nately did not comprise a sufﬁcient number of studies of a high
level Jadad score to justify a performance of subgroup meta-
analyses.
In conclusion, preoperative IVB may represent a new strategy
to make vitrectomy safer and more effective for severe PDR.
RCTs with larger sample sizes or systematic studies are needed
to better evaluate the long-term beneﬁts and safety of bevaci-
zumab pretreatment for severe PDR.
Figure 3 Funnel plot of randomised controlled trials.
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